On September 18, 2021 Epic Sciences, Inc.’s (Epic) Comprehensive Cancer Profiling Platform continues to deliver compelling cell analysis information in clinical trials as data being reported at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate (Press release, Epic Sciences, SEP 18, 2021, View Source [SID1234587939]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data from abstract 577O – "PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)," being presented by Shahneen K. Sandhu, MD, principal investigator of PRINCE and Associate Professor at the Peter MacCallum Cancer Centre, Victoria, Australia, shows that the majority of patients’ circulating tumor cells (CTCs) expressing the target Prostate-Specific Membrane Antigen (PSMA) at baseline were cleared at 12 weeks ,when measured using the Epic PSMA CTC Assay – prior to other response biomarkers in the study.
"CTCs provide a non-invasive tool to track drug-target engagement," said Dr. Sandhu. "This approach could provide complementary information to PET imaging, so that active treatment combinations can be identified in other early phase trials." Biomarker analysis is ongoing in this and other studies comparing the Epic Sciences PSMA CTC Assay with PSMA and FDG PET imaging, and patient outcomes.
The capabilities of Epic’s Comprehensive Cancer Profiling Platform are also highlighted in two ESMO (Free ESMO Whitepaper) 2021 posters with leading global collaborators:
Abstract 613P – Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in mCRPC.
Abstract 614P – Circulating tumor cell (CTC) morphologic sub-types present prior to treatment in the CARD trial identify therapy resistance.